Publishing an article in a scientific journal would be a great success if we were a philanthropic research institute. I was under the impression we are a bio pharmaceutical company.
Will it have an effect? Perhaps, but publishing articles is not our goal.

Congrats tryn2. I hope you have many more days like this. It’s something else’ isn’t it!

As Turtle would say, GO NWBO!

European Clinical Trials has the “GB -no longer in EU/EEA”. I can’t seem to find it in NIH.
Does anyone a link to the trial in Great Britain?

We should ask Sojo.

That was really an astonishing day. I’m like NOOOOO He/She is just joking around!!
OK 2.00 this week and then move that decimal one space, just ONE space to the right next week.

No more joking about $1.00.

On my Fidelity account position NWBO page. It had something like 4,300 bid at 1.40 and ask 5,300 at 1.44 about 2 hours before open.

Now 35 minutes before open it’s 100 each at 1.44 bid 1.45 ask with volume of 1.021

Seems quite large bid/ask totals for so early in the morning.

90 minutes left in today’s session. It will be interesting to see what effect actual “day” traders have exiting their positions as opposed to short term investors that didn’t want to be in over the weekend.

I stand corrected. Thank you very much.

Been a long haul. Best recollection I was down 97% at one point. Averaged down to a cost basis of .72 so yes I’m happy.

Thanks again and best of luck to you on your investments.

They must’ve made an error in the European Clinical trials update. It makes no sense to have your primary and secondary endpoints the same. The way it reads now, there is no PFS comparison to comparable contemporaneous trials only comparison to the control group within the trial.

“E.5.1 Primary end point(s)
The primary endpoint of this study is overall survival (OS) compared between patients randomized to DCVax-L and control patients from comparable, contemporaneous trials who received standard of care therapy only, in patients with newly diagnosed glioblastoma.
E.5.1.1 Timepoint(s) of evaluation of this end point October 2020

E.5.2 Secondary end point(s)
The first secondary endpoint is overall survival (OS) compared between patients randomized to placebo who received DCVax-L treatment following disease recurrence, and control patients from comparable, contemporaneous clinical trials, in patients with recurrent GBM.

The second secondary endpoint, confirmed progression-free survival (cPFS), is confirmed disease progression (cPD) compared between subjects randomized to DCVax®-L and those randomized to Placebo within Study 020221.”

I assume the first secondary endpoint is PFS not OS as published. After everything we’ve seen with this who knows really.

Regards

My Fidelity account had it bid 20,000 shares at 1.51 earlier. Now it shows 17,400 bid at 1.51 with a volume of 2,600. Seems strange.

I don’t recall what the EU trial said before. This seems strange to me.

“ The primary endpoint of this study is overall survival (OS) compared between patients randomized to DCVax-L and control patients from comparable, contemporaneous trials who received standard of care therapy only, in patients with newly diagnosed glioblastoma.”

Has it always been they will compare OS treatment group to control groups that received SOC in different trials?

The second through fifth Secondary endpoints specifically compare the treatment to control group within this study.

“The second secondary endpoint, confirmed progression-free survival (cPFS), is confirmed disease progression (cPD) compared between subjects randomized to DCVax®-L and those randomized to Placebo within Study 020221.”

Regards